|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chuthapisith S, Eremin JM, El-Sheemy M and
Eremin O: Neoadjuvant chemotherapy in women with large and locally
advanced breast cancer: chemoresistance and prediction of response
to drug therapy. Surgeon. 4:211–219. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu Y, Du F, Chen W, Yao M, Lv K and Fu P:
Knockdown of dual specificity phosphatase 4 enhances the
chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to
doxorubicin. Exp Cell Res. 319:3140–3149. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li M, Yin J, Mao N and Pan L: Upregulation
of phosphorylated cofilin 1 correlates with taxol resistance in
human ovarian cancer in vitro and in vivo. Oncol Rep. 29:58–66.
2013.
|
|
5
|
Yvon AM, Wadsworth P and Jordan MA: Taxol
suppresses dynamics of individual microtubules in living human
tumor cells. Mol Biol Cell. 10:947–959. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang TH, Wang HS and Soong YK:
Paclitaxel-induced cell death: where the cell cycle and apoptosis
come together. Cancer. 88:2619–2628. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hopper-Borge E, Chen ZS, Shchaveleva I,
Belinsky MG and Kruh GD: Analysis of the drug resistance profile of
multidrug resistance protein 7 (ABCC10): resistance to docetaxel.
Cancer Res. 64:4927–4930. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rouzier R, Rajan R, Wagner P, et al:
Microtubule-associated protein tau: a marker of paclitaxel
sensitivity in breast cancer. Proc Natl Acad Sci USA.
102:8315–8320. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kastl L, Brown I and Schofield AC:
miRNA-34a is associated with docetaxel resistance in human breast
cancer cells. Breast Cancer Res Treat. 131:445–454. 2012.
View Article : Google Scholar
|
|
10
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Voorhoeve PM: MicroRNAs: oncogenes, tumor
suppressors or master regulators of cancer heterogeneity? Biochim
Biophys Acta. 1805:72–86. 2010.
|
|
12
|
Hao J, Zhao S, Zhang Y, et al: Emerging
role of microRNAs in cancer and cancer stem cells. J Cell Biochem.
115:605–610. 2014. View Article : Google Scholar
|
|
13
|
Blower PE, Chung JH, Verducci JS, et al:
MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer
Ther. 7:1–9. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Iorio MV, Visone R, Di Leva G, et al:
MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yin J, Bai Z, Song J, et al: Differential
expression of serum miR-126, miR-141 and miR-21 as novel biomarkers
for early detection of liver metastasis in colorectal cancer. Chin
J Cancer Res. 26:95–103. 2014.PubMed/NCBI
|
|
16
|
Porkka KP, Pfeiffer MJ, Waltering KK,
Vessella RL, Tammela TL and Visakorpi T: MicroRNA expression
profiling in prostate cancer. Cancer Res. 67:6130–6135. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen X, Wang X, Ruan A, et al: miR-141 is
a key regulator of renal cell carcinoma proliferation and
metastasis by controlling EphA2 expression. Clin Cancer Res.
20:2617–2630. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu Y, Ding Y, Huang J, et al: MiR-141
suppresses the migration and invasion of HCC cells by targeting
Tiam1. PLoS One. 9:e883932014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Imanaka Y, Tsuchiya S, Sato F, Shimada Y,
Shimizu K and Tsujimoto G: MicroRNA-141 confers resistance to
cisplatin-induced apoptosis by targeting YAP1 in human esophageal
squamous cell carcinoma. J Hum Genet. 56:270–276. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
van Jaarsveld MT, Helleman J, Boersma AW,
et al: miR-141 regulates KEAP1 and modulates cisplatin sensitivity
in ovarian cancer cells. Oncogene. 32:4284–4293. 2013. View Article : Google Scholar
|
|
21
|
Brown I, Shalli K, McDonald SL, et al:
Reduced expression of p27 is a novel mechanism of docetaxel
resistance in breast cancer cells. Breast Cancer Res. 6:R601–R607.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Juengel E, Nowaz S, Makarevi J, et al:
HDAC-inhibition counteracts everolimus resistance in renal cell
carcinoma in vitro by diminishing cdk2 and cyclin A. Mol Cancer.
13:1522014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao G, Wang B, Liu Y, et al: miRNA-141,
downregulated in pancreatic cancer, inhibits cell proliferation and
invasion by directly targeting MAP4K4. Mol Cancer Ther.
12:2569–2580. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mateescu B, Batista L, Cardon M, et al:
miR-141 and miR-200a act on ovarian tumorigenesis by controlling
oxidative stress response. Nat Med. 17:1627–1635. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Morales-Prieto DM, Schleussner E and
Markert UR: Reduction in miR-141 is induced by leukemia inhibitory
factor and inhibits proliferation in choriocarcinoma cell line
JEG-3. Am J Reprod Immunol. 66(Suppl 1): S57–S62. 2011. View Article : Google Scholar
|
|
26
|
Zhang L, Deng T, Li X, et al: microRNA-141
is involved in a nasopharyngeal carcinoma-related genes network.
Carcinogenesis. 31:559–566. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Du Y, Xu Y, Ding L, et al: Down-regulation
of miR-141 in gastric cancer and its involvement in cell growth. J
Gastroenterol. 44:556–561. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang HL, Qin XJ, Cao DL, et al: An
elevated serum miR-141 level in patients with bone-metastatic
prostate cancer is correlated with more bone lesions. Asian J
Androl. 15:231–235. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou X, Su J, Zhu L and Zhang G:
Helicobacter pylori modulates cisplatin sensitivity in gastric
cancer by down-regulating miR-141 expression. Helicobacter.
19:174–181. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sonenberg N: eIF4E, the mRNA cap-binding
protein: from basic discovery to translational research. Biochem
Cell Biol. 86:178–183. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thoreen CC: Many roads from mTOR to eIF4F.
Biochem Soc Trans. 41:913–916. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fischer PM: Cap in hand: targeting eIF4E.
Cell Cycle. 8:2535–2541. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mathonnet G, Fabian MR, Svitkin YV, et al:
MicroRNA inhibition of translation initiation in vitro by targeting
the cap-binding complex eIF4F. Science. 317:1764–1767. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Graff JR and Zimmer SG: Translational
control and metastatic progression: enhanced activity of the mRNA
cap-binding protein eIF-4E selectively enhances translation of
metastasis-related mRNAs. Clin Exp Metastasis. 20:265–273. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nasr Z, Robert F, Porco JA Jr, Muller WJ
and Pelletier J: eIF4F suppression in breast cancer affects
maintenance and progression. Oncogene. 32:861–871. 2013. View Article : Google Scholar
|
|
36
|
Furic L, Rong L, Larsson O, et al: eIF4E
phosphorylation promotes tumorigenesis and is associated with
prostate cancer progression. Proc Natl Acad Sci USA.
107:14134–14139. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
De Benedetti A and Graff JR: eIF-4E
expression and its role in malignancies and metastases. Oncogene.
23:3189–3199. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Avdulov S, Li S, Michalek V, et al:
Activation of translation complex eIF4F is essential for the
genesis and maintenance of the malignant phenotype in human mammary
epithelial cells. Cancer Cell. 5:553–563. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kim R, Tanabe K, Emi M, Uchida Y and Toge
T: Modulation of tamoxifen sensitivity by antisense Bcl-2 and
trastuzumab in breast carcinoma cells. Cancer. 103:2199–2207. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Huang Y, Ray S, Reed JC, et al: Estrogen
increases intracellular p26Bcl-2 to p21Bax ratios and inhibits
taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast
Cancer Res Treat. 42:73–81. 1997. View Article : Google Scholar : PubMed/NCBI
|
